Results of a clinical study of the combination of flurbiprofen and cetylpyridinium chloride in patients with sore throat

Galustyan A.N.; Sedavnykh I.S.; Gonik M.I.

doi:https://doi.org/10.17116/otorino20228702122

Galustyan A.N.

St. Petersburg State Pediatric Medical University

Sedavnykh I.S.

City polyclinic No. 51

Gonik M.I.

Otisipharm JSC

Results of a clinical study of the combination of flurbiprofen and cetylpyridinium chloride in patients with sore throat

Authors:

Galustyan A.N., Sedavnykh I.S., Gonik M.I.

More about the authors

Journal: Russian Bulletin of Otorhinolaryngology. 2022;87(2): 22‑28

DOI: 10.17116/otorino20228702122

Read: 1548 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Galustyan AN, Sedavnykh IS, Gonik MI. Results of a clinical study of the combination of flurbiprofen and cetylpyridinium chloride in patients with sore throat. Russian Bulletin of Otorhinolaryngology. 2022;87(2):22‑28. (In Russ.)
https://doi.org/10.17116/otorino20228702122

Подписка 2026 Вестник оториноларингологии (Russian Bulletin of Otorhinolaryngology)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To evaluate the efficacy and safety of a combined topical drug with flurbiprofen and cetylpyridinium chloride in patients with sore throat caused by upper respiratory tract infections.

MATERIAL AND METHODS

A prospective multicenter open randomized comparative study in parallel groups included 266 adult patients with an established diagnosis of acute pharyngitis or acute tonsillitis aged 18 to 60 years with the main complaint of sore throat caused by viral infections of the upper respiratory tract. The patients included in the study were randomized into two groups of 133 participants each: the 1st group included patients who received the combined agent flurbiprofen 8.75 mg and cetylpyridinium chloride 1.00 mg in the form of tablets for resorption, the 2nd group included patients who received cetylpyridinium chloride 1.2 mg in the form of medicinal lozenges. The effectiveness was evaluated on several scales (RADT, STPIS, TPA, STPR) reflecting subjective and objective indicators of the dynamics of the disease.

RESULTS

The studied combination proved to be more effective than the monocomponent agent and was characterized by a more pronounced decrease in sore throat within 2 hours after taking the drug and a decrease in pharyngeal hyperemia.

CONCLUSION

According to the results of the study, the use of a drug based on a combination of flurbiprofen and cetylpyridinium chloride was accompanied by a rapid and pronounced decrease in sore throat and pharyngeal hyperemia in patients with upper respiratory tract infections.

Keywords:

sore throat

upper respiratory tract infections

cetylpyridinium chloride

flurbiprofen

Authors:

Galustyan A.N.

St. Petersburg State Pediatric Medical University

Sedavnykh I.S.

City polyclinic No. 51

Gonik M.I.

Otisipharm JSC

Received:

16.02.2022

Accepted:

20.04.2022

Close metadata

References:

Ovchinnikov AYu, Miroshnichenko NA, Nikolaeva YuO. Sore throat. Recent trends in treatment. Vestnik otorinolaringologii. 2020;85(4):35-39. (In Russ.). https://doi.org/10.17116/otorino20208504135
Slavsky AN, Meitel IYu. Sore throat: rationale for the optimal choice of drug. Medical Council. 2016;18:128-132. (In Russ.). https://doi.org/10.21518/2079-701X-2016-18-128-132
Turovsky AB. Treatment of sore throat. Spravochnik poliklinicheskogo vracha. 2012;3:28-30. (In Russ).
Benrimoj SI, Langford JH, Christian J, Charlesworth A, Steans A. Efficacy and tolerability of the anti-inflammatory throat lozenge Flurbiprofen 8.75 mg in the treatment of sore throat. Clinical Drug Investigation. 2001;21(3):183-193. https://doi.org/10.2165/00044011-200121030-00004
Watson N, Nimmo WS, Christian J, Charlesworth A, Speight J, Miller K. Relief of sore throat with the anti-inflammatory throat lozenge flurbiprofen 8.75 mg: A randomised, double-blind, placebo-controlled study of efficacy and safety. International Journal of Clinical Practice. 2000;54(8):490-496.
Schachtel B, Aspley S, Shephard A, Shea T, Smith G, Sanner K, Savino L, Rezuke J, Schachtel E. Onset of action of a lozenge containing flurbiprofen 8.75 mg: A randomized, double-blind, placebo-controlled trial with a new method for measuring onset of analgesic activity. Pain. 2014;155(2):422-428. https://doi.org/10.1016/j.pain.2013.11.001
Lebedinskaya EA, Utkina NP, Merzlova NB, Lebedinskaya OV. Evaluation of the effectiveness of drugs containing cetylpyridinium chloride in local therapy of acute pharyngitis, laryngitis and catarrhal sore throat in children. Voprosy sovremennoj pediatrii. 2013;12(1):177-180. (In Russ.).
Jia Z, Shen D, Xu W. Synthesis and antibacterial activities of quaternary ammonium salt of chitosan. Carbohydrate Research. 2001;333(1):1-6. https://doi.org/10.1016/S0008-6215(01)00112-4
Abedon ST. Specific Antimicrobials. Ohio State University; 2008. Retrieved December 2008. Accessed April 11, 2022. https://web.archive.org/web/20081015002934/https://www.mansfield.ohio-state.edu/~sabedon/biol2032.htm
Geppe NA, Karpova EP, Dronov IA, Kovalenko EA, Botneva AV, Terent’ev VA, Velikoreckaya MD, Kolosova NG. Topical drugs for the treatment of non-streptococcal acute tonsillopharyngitis in children: results of a multicenter study. Vestnik Oto-Rino-Laringologii. 2020;85(6):84-89. (In Russ.). https://doi.org/10.17116/otorino20208506184
Svistushkin VM, Nikiforova GN, Shevchik EA, Toporkova LA. Efficacy of topical drugs in the treatment of patients with acute inflammatory diseases of the pharynx. Vestnik otorinolaringologii. 2019;84(6):112-117. (In Russ.). https://doi.org/10.17116/otorino201984061112
Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ (Clinical Research ed.). 2010;340:332. https://doi.org/10.1136/bmj.c332